Update on cryptosporidiosis research program. (CryptoGAM)

ImmuCell Corporation, Portland, Maine, announced that in September 1994 the company and its partner, Univax Biologics Inc., completed enrollment in a Phase I/II clinical trial of CryptoGAM, a bovine-derived specific polyclonal antibody against the cryptosporidiosis parasite that is often responsible for severe diarrhea in advanced AIDS patients.

This trial examined the effect of treatment with CryptoGAM delivered directly to the duodenum. The preliminary results of this study indicate that although the patients experienced significant reductions in overall parasite counts, there was no significant reduction in clinical symptoms.

"The results we have obtained …